News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026April 22, 2026 Nexalis Therapeutics – formerly InhaleRx – has completed dosing in the first cohort of its Phase […]
InhaleRx eyes big pharma deal and ponders product launch through SAS by Steve Jones March 18, 2025March 18, 2025
InhaleRx prepares for pivotal trial in quest to provide relief from breakthrough cancer pain by cannabiz team January 29, 2025January 31, 2025
